Ozempic and Gastroparesis: Understanding the Reported Link

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Systemic Concern

If you take Ozempic and have noticed persistent nausea, vomiting, or abdominal pain, you may be wondering about gastroparesis. Clinical and regulatory reports have increasingly examined this potential side effect. The tradition of medical surveillance and post-market safety monitoring provides a framework for understanding these emerging findings. This page reviews what current reports indicate about Ozempic-associated gastroparesis and how to approach these concerns with your healthcare provider.

The Bridge Between Legacy Information and Legal Accountability

This pivot underscores the need to examine how mass production environments—where consistent drug availability and patient adherence are prioritized—may inadvertently amplify risks that were previously considered rare. The bridge between legacy health information and occupational exposure lies in recognizing that the same medication, when produced and prescribed at scale, can transform a personal health decision into a systemic concern requiring regulatory and legal attention. For patients in Texas, understanding the statute of limitations is critical for preserving their right to seek compensation for Ozempic-associated gastroparesis.

Ozempic and Gastroparesis: Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action includes delayed gastric emptying, which is a known effect of GLP-1 receptor agonists. This delay can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation of gastroparesis often overlaps with common gastrointestinal adverse effects reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which may reflect the drug's effect on gastric motility.

Mechanism and Diagnosis of Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gastrointestinal tract, which slows gastric emptying. While this effect is intended to improve glycemic control by reducing postprandial glucose excursions, it can become pathological in some patients, leading to symptomatic gastroparesis. The diagnosis of gastroparesis typically requires objective measurement of delayed gastric emptying, such as via gastric emptying scintigraphy, and exclusion of other causes. Patients who develop persistent nausea, vomiting, or abdominal pain after starting Ozempic should be evaluated for gastroparesis. The timeline between exposure and documented harm can vary; some patients may experience symptoms during dose escalation, while others may develop symptoms after prolonged use. The label notes that the majority of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but gastroparesis may develop later and persist even after discontinuation.

Adequacy of Warnings and Legal Implications

Regarding the adequacy of warnings, the Ozempic label does not explicitly list gastroparesis as a warning or precaution. The label includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported and that anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, it does not specifically warn about the risk of gastroparesis. The gastrointestinal adverse reactions section lists common symptoms but does not characterize them as potential indicators of gastroparesis. This lack of explicit warning may affect settlement-related considerations for affected patients, as it could be argued that the manufacturer did not adequately inform prescribers and patients about the risk of developing gastroparesis.

Statute of Limitations for Ozempic Claims in Texas

For patients in Texas considering a settlement related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. In Texas, the statute of limitations for personal injury claims, including product liability, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. This means that patients who developed gastroparesis after using Ozempic must file a claim within two years of recognizing the link between their symptoms and the medication. The timeline between exposure and documented harm is important for determining when the statute of limitations begins. If a patient experienced gastrointestinal symptoms during dose escalation but did not receive a formal diagnosis of gastroparesis until later, the clock may start at the date of diagnosis or when the patient first suspected the drug caused their condition. Patients should consult with a legal professional to assess their specific circumstances.

Settlement Considerations and Evidence Strength

Settlement-related considerations also include the strength of the evidence linking Ozempic to gastroparesis. The clinical trial data show a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, and the pharmacological mechanism supports a causal relationship. However, the label does not explicitly warn about gastroparesis, which may strengthen claims of inadequate warnings. Patients who have documented medical records showing a temporal relationship between Ozempic use and the onset of gastroparesis, along with objective diagnostic testing, may have stronger cases. The frequency of gastrointestinal adverse reactions, including those that could be precursors to gastroparesis, is dose-dependent, as seen in the higher rates with 2 mg versus 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This dose-response relationship may be used to support causation. In summary, patients in Texas who developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery. The evidence from clinical trials indicates a higher rate of gastrointestinal adverse reactions with Ozempic, and the label does not explicitly warn about gastroparesis. These factors may influence settlement negotiations. Patients should seek legal advice promptly to preserve their rights. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including product liability, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. Patients who developed gastroparesis after using Ozempic must file a claim within two years of recognizing the link between their symptoms and the medication.

Does the Ozempic label warn about gastroparesis?

No, the Ozempic label does not explicitly list gastroparesis as a warning or precaution. It lists common gastrointestinal adverse reactions but does not characterize them as potential indicators of gastroparesis. This lack of explicit warning may affect settlement considerations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.